Clinical Trials Logo

Advanced Parkinson's Disease clinical trials

View clinical trials related to Advanced Parkinson's Disease.

Filter by:

NCT ID: NCT06195124 Recruiting - Clinical trials for Advanced Parkinson's Disease

A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease

Start date: December 2023
Phase: Early Phase 1
Study type: Interventional

A safety study in patients with Parkinson's disease.

NCT ID: NCT04802733 Active, not recruiting - Clinical trials for Advanced Parkinson's Disease

Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

Start date: May 3, 2021
Phase: Phase 1
Study type: Interventional

This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.

NCT ID: NCT03007888 Completed - Clinical trials for Advanced Parkinson's Disease

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

Start date: November 14, 2016
Phase: Phase 2
Study type: Interventional

Primary Objective: To compare the pharmacokinetics (PK) of single and multiple doses of IPX203 with Immediate release carbidopa-levodopa (IR CD-LD) in subjects with advanced Parkinson's disease (PD). Secondary Objectives: To compare the pharmacodynamics of single and multiple doses of IPX203 with IR CD-LD. To compare the efficacy of IPX203 with IR CD-LD following multiple doses. To evaluate the safety of IPX203.

NCT ID: NCT02611713 Completed - Clinical trials for Advanced Parkinson's Disease

Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease

DUOGLOBE
Start date: January 4, 2016
Phase:
Study type: Observational

This study is a non-interventional post-marketing observational study (PMOS) of participants with advanced Parkinson's disease (PD) treated with Duodopa/Duopa in a routine clinical setting. Effectiveness of treatment will be collected with physician and participant/caregiver health outcomes beginning with PMOS enrollment (baseline visit), at the start of Duodopa/Duopa treatment via percutaneous endoscopic gastrostomy-with jejunal extension (PEG-J), at regularly scheduled visits closest to Months 3 and 6, and every 6 months thereafter up to 36 months. An additional cohort of participants will be enrolled who in addition will be evaluated with a wearable device.

NCT ID: NCT02549092 Completed - Clinical trials for Advanced Parkinson's Disease

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

Start date: October 26, 2015
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.

NCT ID: NCT02154724 Recruiting - Clinical trials for Advanced Parkinson's Disease

Clinical Study for Adaptive Deep Brain Stimulation (aDBS)Controlled by Intracerebral Activity in Parkinson's Disease

ADBS
Start date: September 2013
Phase: N/A
Study type: Interventional

Despite its therapeutic effectiveness in Parkinson's disease (PD) the current deep brain stimulation (DBS) strategy could achieve an even better clinical result by adapting to patient's condition. As intracerebral activity analyzed by recording local field potentials (LFPs) from DBS electrodes correlates to PD symptoms, a new stimulation approach would be an "intelligent" adaptive DBS system able to change stimulation settings automatically to the patient's needs using LFPs as control variable.

NCT ID: NCT02082249 Completed - Clinical trials for Advanced Parkinson's Disease

An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Start date: March 10, 2014
Phase: Phase 3
Study type: Interventional

This is an extension study to evaluate the long-term safety and tolerability of ABT-SLV187 in subjects with advanced Parkinson's disease.

NCT ID: NCT01960842 Completed - Clinical trials for Advanced Parkinson's Disease

A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Start date: October 2013
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to measure the efficacy of ABT-SLV187 in subjects with advanced Parkinson's disease.

NCT ID: NCT01736176 Completed - Clinical trials for Advanced Parkinson's Disease

A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease

Start date: March 2013
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate change in non-motor symptoms from baseline to Week 12 as measured by the Non-Motor Symptom Scale total score.

NCT ID: NCT01723904 Completed - Clinical trials for Advanced Parkinson's Disease

A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease

Start date: October 2012
Phase: Phase 3
Study type: Interventional

This study is to investigate the safety and efficacy of Rotigotine add-on therapy with low doses of Pramipexole or Ropinirole in patients with advanced-stage Parkinson's Disease (PD) who have insufficient response to L-dopa and low doses dopamine receptor agonists.